Pharmaceuticals Stocks
Entities in this sector focus on the discovery, development, and commercialization of chemical and biological therapies to treat specific disease states. Revenue models hinge on successful clinical trial progression, intellectual property protection, and regulatory approval pathways that define market exclusivity periods.
As of Oct 23, 2026, Pharmaceuticals has 350 US-listed companies worth $7T combined. The median member moved +0.6% over the past week; ARGX led among the 25 largest at +6.7% and MRNA trailed at -8.2%.
Companies in Pharmaceuticals
- LLY – Eli Lilly and Company, $1.1T
- JNJ – Johnson & Johnson, $645B
- ABBV – AbbVie Inc, $505B
- MRK – Merck & Company Inc, $363B
- PM – Philip Morris International Inc, $314B
- NVS – Novartis AG ADR, $287B
- AZN – AstraZeneca PLC, $266B
- TMO – Thermo Fisher Scientific Inc, $249B
- AMGN – Amgen Inc, $237B
- GILD – Gilead Sciences Inc, $193B
- ABT – Abbott Laboratories, $177B
- NVO – Novo Nordisk A/S, $172B
- PFE – Pfizer Inc, $171B
- VRTX – Vertex Pharmaceuticals Inc, $136B
- BMY – Bristol-Myers Squibb Company, $129B
- CVS – CVS Health Corp, $121B
- MCK – McKesson Corporation, $117B
- GSK – GlaxoSmithKline PLC ADR, $103B
- SNY – Sanofi ADR, $99.7B
- REGN – Regeneron Pharmaceuticals Inc, $82.9B
- MRNA – Moderna Inc, $79.9B
- COR – Cencora Inc., $65B
- TAK – Takeda Pharmaceutical Co Ltd ADR, $64.7B
- CAH – Cardinal Health Inc, $59.2B
- ARGX – argenx NV ADR, $54.9B
- GALDY – GALDERMA GROUP AG, $54B
- VEEV – Veeva Systems Inc Class A, $52.2B
- A – Agilent Technologies Inc, $48.8B
- TEVA – Teva Pharma Industries Ltd ADR, $46B
- WAT – Waters Corporation, $44.9B
- ONC – BeiGene, Ltd., $43B
- KR – Kroger Company, $40.1B
- BIIB – Biogen Inc, $37B
- RPRX – Royalty Pharma Plc, $36.8B
- ZTS – Zoetis Inc, $33.9B
- GEHC – GE HealthCare Technologies Inc., $32.5B
- ALNY – Alnylam Pharmaceuticals Inc, $30B
- WST – West Pharmaceutical Services Inc, $27.7B
- LH – Laboratory Corporation of America Holdings, $26.7B
- UTHR – United Therapeutics Corporation, $25.1B
- INCY – Incyte Corporation, $23.7B
- VTRS – Viatris Inc, $21.2B
- INSM – Insmed Inc, $20.4B
- MEDP – Medpace Holdings Inc, $18.3B
- RVTY – Revvity Inc., $17.7B
- CRL – Charles River Laboratories, $16.6B
- EXEL – Exelixis Inc, $16.2B
- ASND – Ascendis Pharma AS, $16B
- NBIX – Neurocrine Biosciences Inc, $14.6B
- ICLR – ICON PLC, $14.3B
- JAZZ – Jazz Pharmaceuticals PLC, $13.9B
- BBIO – BridgeBio Pharma Inc, $13.4B
- BAX – Baxter International Inc, $13.3B
- BTSG – BrightSpring Health Services, Inc. Common Stock, $12B
- AVTR – Avantor Inc, $11.7B
- CORT – Corcept Therapeutics Incorporated, $11.6B
- ELAN – Elanco Animal Health, $11.3B
- RDY – Dr. Reddy’s Laboratories Ltd ADR, $11B
- BMRN – Biomarin Pharmaceutical Inc, $10.8B
- GKOS – Glaukos Corp, $10.4B
- MDGL – Madrigal Pharmaceuticals Inc, $10B
- BIO – Bio-Rad Laboratories Inc, $9.6B
- KYMR – Kymera Therapeutics Inc, $9.3B
- CYTK – Cytokinetics Inc, $8.5B
- ARWR – Arrowhead Pharmaceuticals Inc, $8.2B
- ATR – AptarGroup Inc, $8.1B
- ABVX – Abivax SA American Depositary Shares, $7.7B
- SHMXY – Shimadzu Corp, $7.6B
- AXSM – Axsome Therapeutics Inc, $7.6B
- ALKS – Alkermes Plc, $7.4B
- IONS – Ionis Pharmaceuticals Inc, $7.3B
- AMRX – Amneal Pharmaceuticals, Inc. Class A Common Stock, $7.1B
- LNTH – Lantheus Holdings Inc, $6.5B
- IOVA – Iovance Biotherapeutics Inc, $6.4B
- RYTM – Rhythm Pharmaceuticals Inc, $6.3B
- BLCO – Bausch + Lomb Corp, $6.2B
- BLTE – Belite Bio Inc ADR, $5.8B
- SXT – Sensient Technologies Corporation, $5.6B
- STVN – Stevanato Group SpA, $5.5B
- MIRM – Mirum Pharmaceuticals Inc, $5.3B
- PTCT – PTC Therapeutics Inc, $5.3B
- GRFS – Grifols SA ADR, $5.2B
- ERAS – Erasca Inc, $5.1B
- TVTX – Travere Therapeutics Inc, $4.9B
- DFTX – Definium Therapeutics, Inc., $4.4B
- INDV – Indivior PLC Ordinary Shares, $4.2B
- ARQT – Arcutis Biotherapeutics Inc, $4B
- OGN – Organon & Co, $3.6B
- LQDA – Liquidia Technologies Inc, $3.6B
- XENE – Xenon Pharmaceuticals Inc, $3.5B
- ACAD – ACADIA Pharmaceuticals Inc, $3.5B
- IDYA – Ideaya Biosciences Inc, $3.5B
- ASH – Ashland Global Holdings Inc, $3.4B
- TARS – Tarsus Pharmaceuticals Inc, $3.3B
- VKTX – Viking Therapeutics Inc, $3.3B
- CELC – Celcuity LLC, $3.2B
- ZLAB – Zai Lab Ltd, $2.7B
- MBX – MBX Biosciences, Inc. Common Stock, $2.5B
- GRDN – Guardian Pharmacy Services, Inc., $2.5B
- HCM – HUTCHMED DRC, $2.5B
- SUPN – Supernus Pharmaceuticals Inc, $2.4B
- BHC – Bausch Health Companies Inc, $2.4B
- ADMA – ADMA Biologics Inc, $2.4B
- SLS – Sellas Life Sciences Group Inc, $2.3B
- PRGO – Perrigo Company PLC, $2.3B
- AGIO – Agios Pharm, $2.2B
- AUPH – Aurinia Pharmaceuticals Inc, $2.2B
- FTRE – Fortrea Holdings Inc., $2.1B
- NEO – NeoGenomics Inc, $2.1B
- HRMY – Harmony Biosciences Holdings, $2.1B
- PHVS – Pharvaris BV, $2.1B
- TRLV – Trulieve Cannabis Corp., $2.1B
- XERS – Xeris Pharmaceuticals Inc, $2B
- BCRX – BioCryst Pharmaceuticals Inc, $2B
- MLYS – Mineralys Therapeutics, Inc. Common Stock, $1.9B
- ALVO – Alvotech, $1.9B
- NVAX – Novavax Inc, $1.9B
- TRVI – Trevi Therapeutics Inc, $1.8B
- MESO – Mesoblast Ltd, $1.7B
- NUVB – Nuvation Bio Inc, $1.7B
- KLRA – Kailera Therapeutics, Inc. Common Stock, $1.7B
- URGN – UroGen Pharma Ltd, $1.7B
- ANIP – ANI Pharmaceuticals Inc, $1.7B
- OCUL – Ocular Therapeutix Inc, $1.7B
- ETON – Eton Pharmaceuticals Inc, $1.6B
- GPCR – Structure Therapeutics Inc. American Depositary Shares, $1.6B
- CMPS – Compass Pathways Plc, $1.6B
- RARE – Ultragenyx, $1.6B
- IMCR – Immunocore Holdings Ltd, $1.5B
- TYRA – Tyra Biosciences Inc, $1.5B
- AZTA – Azenta Inc, $1.5B
- INVA – Innoviva Inc, $1.5B
- PAHC – Phibro Animal Health Corporation, $1.4B
- ORIC – Oric Pharmaceuticals Inc, $1.2B
- MNKD – MannKind Corp, $1.2B
- LBRX – LB Pharmaceuticals Inc Common Stock, $1.2B
- OPK – Opko Health Inc, $1.2B
- SNDX – Syndax Pharmaceuticals Inc, $1.2B
- HROW – Harrow Health Inc, $1.1B
- GDRX – Goodrx Holdings Inc, $1.1B
- AMPH – Amphastar P, $1.1B
- LTGO – Latigo Biotherapeutics, Inc. Common Stock, $1.1B
- SVRA – Savara Inc, $1B
- PCRX – Pacira BioSciences, Inc., $1B
- KURA – Kura Oncology Inc, $944M
- RIGL – Rigel Pharmaceuticals Inc, $881M
- CYRX – Cryoport Inc, $879M
- ODTX – Odyssey Therapeutics, Inc. Common Stock, $871M
- JBIO – Jade Biosciences, Inc., $853M
- ARDX – Ardelyx Inc, $842M
- AVBP – ArriVent BioPharma, Inc. Common Stock, $821M
- HELP – Cybin Inc., $799M
- LXRX – Lexicon Pharmaceuticals Inc, $783M
- VSTM – Verastem Inc, $781M
- APMD – Apnimed, Inc. Common Stock, $771M
- GERN – Geron Corporation, $771M
- ACHV – Achieve Life Sciences Inc, $729M
- ANNX – Annexon Inc, $726M
- MLAB – Mesa Laboratories Inc, $722M
- GYRE – Gyre Therapeutics Inc., $717M
- COLL – Collegium Pharmaceutical Inc, $701M
- PHAR – Pharming Group NV, $690M
- OLMA – Olema Pharmaceuticals Inc, $684M
- ZVRA – Zevra Therapeutics Inc., $676M
- SGMT – Sagimet Biosciences Inc. Series A Common Stock, $633M
- IRWD – Ironwood Pharmaceuticals Inc, $620M
- AQST – Aquestive Therapeutics Inc, $579M
- CRMD – CorMedix Inc, $576M
- PHAT – Phathom Pharmaceuticals Inc, $551M
- DCTH – Delcath Systems Inc, $534M
- VALN – Valneva SE ADR, $527M
- PBYI – Puma Biotechnology Inc, $506M
- DRUG – Bright Minds Biosciences Inc, $506M
- MNPR – Monopar Therapeutics Inc, $498M
- TKNO – Alpha Teknova Inc, $468M
- KMDA – Kamada, $466M
- DMAC – DiaMedica Therapeutics Inc, $449M
- TLRY – Tilray Inc, $432M
- SPRY – ARS Pharmaceuticals, Inc, $427M
- AVIR – Atea Pharmaceuticals Inc, $413M
- ASMB – Assembly Biosciences Inc, $409M
- SLP – Simulations Plus Inc, $374M
- FENC – Fennec Pharmaceuticals Inc, $358M
- EBS – Emergent Biosolutions Inc, $354M
- RLMD – Relmada Therapeutics Inc, $347M
- BNTC – Benitec Biopharma Ltd ADR, $335M
- IRD – Opus Genetics, Inc., $318M
- ASPI – ASP Isotopes Inc. Common Stock, $315M
- ARCT – Arcturus Therapeutics Holdings Inc, $308M
- VNDA – Vanda Pharmaceuticals Inc, $273M
- CTNM – Contineum Therapeutics, Inc. Class A Common Stock, $266M
- CUVL – Clinuvel Pharmaceuticals Limited American Depositary Shares, $262M
- AMRN – Amarin Corporation PLC, $261M
- ACB – Aurora Cannabis Inc, $253M
- ABEO – Abeona Therapeutics Inc, $252M
- IKT – Inhibikase Therapeutics Inc, $251M
- PALI – Palisade Bio Inc, $251M
- LFCR – Lifecore Biomedical Inc., $248M
- XFOR – X4 Pharmaceuticals Inc, $243M
- SIGA – SIGA Technologies Inc, $234M
Showing the 200 largest of 350 members by market cap.